Doug MBA - BiOasis Technologies Exec Officer
| BIOAF Stock | USD 0.0001 0.00 0.00% |
Insider
Doug MBA is Exec Officer of biOasis Technologies
| Phone | 203 533 7082 |
| Web | https://www.bioasis.us |
BiOasis Technologies Management Efficiency
The company has return on total asset (ROA) of (0.8058) % which means that it has lost $0.8058 on every $100 spent on assets. This is way below average. BiOasis Technologies' management efficiency ratios could be used to measure how well BiOasis Technologies manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Michael Pitzner | Molecular Partners AG | N/A | |
| Edward Calamai | DiaMedica Therapeutics | N/A | |
| Dominic Cundari | DiaMedica Therapeutics | 73 | |
| Justin Trojanowski | Tempest Therapeutics | 36 | |
| Anne Moon | Tempest Therapeutics | N/A | |
| Steven Ruhl | Forte Biosciences | 67 | |
| Dr Dubensky | Tempest Therapeutics | 66 | |
| Joseph Hazelton | Dyadic International | 48 | |
| Seth Lewis | Molecular Partners AG | N/A | |
| Andreas EMBA | Molecular Partners AG | 58 | |
| Daniel Ryweck | Silo Pharma | 59 | |
| Alexander Zurcher | Molecular Partners AG | 49 | |
| Robyn Sweinhart | Rezolute | N/A | |
| Petpiboon Prasit | Tempest Therapeutics | N/A | |
| MD MBA | Rezolute | N/A | |
| , MBA | Molecular Partners AG | 51 | |
| Antony CPA | Forte Biosciences | 57 | |
| Scott CA | DiaMedica Therapeutics | 59 | |
| Thomas Schwerzmann | Molecular Partners AG | N/A | |
| Christopher Roenfeldt | Forte Biosciences | N/A | |
| Patrick Amstutz | Molecular Partners AG | 49 | |
Management Performance
| Return On Asset | -0.81 |
biOasis Technologies Leadership Team
Elected by the shareholders, the BiOasis Technologies' board of directors comprises two types of representatives: BiOasis Technologies inside directors who are chosen from within the company, and outside directors, selected externally and held independent of BiOasis. The board's role is to monitor BiOasis Technologies' management team and ensure that shareholders' interests are well served. BiOasis Technologies' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, BiOasis Technologies' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Kim Elton, Director Marketing | ||
| Mei Tian, VP Research | ||
| Graeme Dick, Director Relations | ||
| Doug MBA, Exec Officer | ||
| Dave Jenkins, Chief Officer | ||
| B FTSE, CEO Chairman |
BiOasis Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is BiOasis Technologies a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | -0.81 | |||
| Operating Margin | (11.41) % | |||
| Current Valuation | 6 M | |||
| Shares Outstanding | 79.41 M | |||
| Shares Owned By Insiders | 2.05 % | |||
| Price To Earning | 13.82 X | |||
| Price To Book | 53.47 X | |||
| Price To Sales | 26.52 X | |||
| Revenue | 37.73 K | |||
| Gross Profit | (1.15 M) |
Currently Active Assets on Macroaxis
Other Information on Investing in BiOasis Pink Sheet
BiOasis Technologies financial ratios help investors to determine whether BiOasis Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in BiOasis with respect to the benefits of owning BiOasis Technologies security.